Natural killer cells, also known as NK cells or large granular lymphocytes (LGL), are a type of cytotoxic lymphocyte critical to the innate immune system that belongs to the rapidly expanding family of known innate lymphoid cells (ILC) and represents 5–20% of all circulating lymphocytes in humans. The role of NK cells is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells respond rapidly to virus-infected cells and other intracellular pathogens acting around 3 days after infection and respond to tumor formation. NK Cell Stimulators enhance the cytotoxic (cell-killing) activity of NK cells. They can promote the release of cytotoxic molecules, such as perforin and granzymes, by NK cells. These molecules help destroy target cells, including infected cells and cancer cells. NK Cell Stimulator is used in the treatment of carcinoma, lymphoma, sarcoma, endocrine gland neoplasm, digestive system diseases, respiratory tract neoplasm, skin diseases, breast diseases, ovarian cancer, prostatic diseases, kidney diseases, hematologic diseases, and lung neoplasms.
Increased prevalence of life-threatening cancers, tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity are the key drivers for the NK Cell Stimulator market. For instance, according to the World Health Organization 2020, there were 2.26 million new cases of breast cancer and 1.41 million cases of prostate cancer worldwide. The introduction of newer products by market players may look for opportunities that greatly impact comprehensive research and development in NK Cell Stimulator inhibitors. For instance, Clinigen launched Proleukin (Aldesleukin) to treat renal carcinoma. Moreover, numerous market participants are developing innovative compounds to address the difficulties in therapy. For instance, ImmunityBio’s GI 4000 for the indication of various cancers is under the various stages of clinical studies.
Key Market Developments:
- In May 2023, Eli Lilly in collaboration with EMD Serono, researched finding shows that combined radiotherapy and antibody-based immunotherapy with expanded NK cells may be an effective strategy to enhance the efficiency of treatment against colorectal cancer.
Approved Drug Molecules and Brand Names for NK Cell Stimulator:
Proleukin (Aldesleukin)
Drugs under the Pipeline for NK Cell Stimulator:
- NK92-CD16-158V
- GI 4000
- Bempegaldesleukin (NKTR-214)
- Removab (Catumaxomab)
- Monalizumab (IPH2201)
- Lirilumab (BMS-986015)
- Mosedipimod (EC-18)
- AFM13
- Alecsat (cytotoxic lymphocyte-based cancer vaccine)
- CYAD-01
- MEDI0457
- MG4101
- SNK01
- High-Activity Natural Killer Cell Therapy
- Nemvaleukin Alfa (Alks 4230)
- Talacotuzumab (Jnj-56022473)
- CIML NK cells
- FT538
- HemaMax (rHuIL-12)
- PD-L1.t-haNK
- SAR445419
- Lacutamab (IPH4102)
- Taniraleucel (CYNK-001)
- FT516
- Delolimogene Mupadenorepvec (LOAd703)
- hI-con1 (ICON-1)
- oNKord (GCT NK cells)
- AgenT-797
- CIML NK
- CST-101
- FATE-NK100
- FT596
- GAIA-102
- GEN-001
- KappaMab
- NKG2D CAR-NK cell therapy
- ROBO1 CAR-NK cells
- ToleroVax (alpha-galactosylceramide liposomal)
- Urocidin (Mycobacterium Cell Wall-DNA complex)
- WU-NK-101
- XmAb306
- Nanrilkefusp Alfa (SOT101)
- AB-101
- ASP7517
- 70
- CB CAR-NK019
- CC-700C
- t-haNK
- CellProtect (evencaleucel)
- DVX201
- FT500
- GDA-201
- IBR900
- KUR-501
- KUR-502
- NIZ985
- PNK-007
- QN-023a
- QN-030a
- SMT-NK
- SZ011
Clinical Activity and Developments of NK Cell Stimulator:
Till July 2023, there will be about more than 100 companies with over 150 compounds that focus on various forms of lymphoma and sarcoma. For these molecules, more than 500 clinical trials are being conducted, and the majority are in phase-2, and phase-3 clinical trials by players across the globe. For instance,
- In February 2023, Bristol-Myers Squibb completed phase 3, a randomized study of neoadjuvant and adjuvant nivolumab plus NKTR-214 Versus Nivolumab alone versus standard of care in participants with muscle-invasive bladder cancer (MIBC).
- In March 2020, Bristol-Myers Squibb completed phase 1/2 of a study of the combination of Lirilumab (anti-KIR) plus Nivolumab (Anti-PD-1) or Lirilumab plus Nivolumab and Ipilimumab in advanced refractory solid tumors.
|
Molecule Name |
Number of Studies |
|
NK92-CD16-158V |
22 |
|
GI 4000 |
21 |
|
Bempegaldesleukin (NKTR-214) |
21 |
|
Removab (Catumaxomab) |
20 |
|
Monalizumab (IPH2201) |
20 |
Target Indication Analysis of NK Cell Stimulator
Clinigen, a human recombinant interleukin-2 product, developed the molecules such as Proleukin (Aldesleukin). Proleukin is specifically indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC) and adults with metastatic melanoma.Proleukin is supplied as an intravenous infusion. Many other molecules like Bempegaldesleukin (NKTR-214) and Removab (Catumaxomab) are under clinical development for carcinoma and sarcoma.
Regional Analysis
Natural killer Cell Stimulator Market
Total sales of Clinigen’s Proleukin (Aldesleukin) for the entire year ended at US$60 million in FY2018. Novartis has signed an agreement to divest the US rights to its Proleukin (aldesleukin) medicine to UK-based Clinigen Group for a total cash consideration of up to USD 210 Million in 2019, and Clinigen already owns the rights to Proleukin outside the US which it acquired in July 2018. With the deal, Clinigen will be the exclusive global owner of the licensed version of this drug, which is being used in multiple drug studies across different disease areas. But Clinigen divested Proleukin to Lovance Biotherapeutics for GBP 166.7 million in January 2023. Moreover, the increased incidence of cancers due to smoking, ongoing lifestyles, and increasing global reimbursement policies Seem to create an opportunity for the future and burgeon the growth of the NK Cell Stimulator market. For instance, according to Research Findings 2021, an estimated 19.3 million new cancer cases have been diagnosed globally, which is expected to Create a lucrative opportunity for the NK Cell Stimulator market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Proleukin (Aldesleukin) is the only FDA-approved NK Cell Stimulator.
Total sales of Clinigen’s Proleukin (Aldesleukin) for the full year ended were USD 60 million in FY2018 in the US.
Clinigen, Merck (MSD), Novartis, Lovance Biotherap, etc are few leading market players in NK Cell Stimulator market.
carcinoma, lymphoma, sarcoma, endocrine gland neoplasm, digestive system diseases, respiratory tract neoplasm, skin diseases, breast diseases, ovarian cancer, etc are the major indication of NK Cell Stimulator.
There are more than 100 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.
- Clinigen
- Merck (MSD)
- Novartis
- Lovance Biotherap
- Eisai
- ImmunityBio
- BMS
- Ono Pharma
- NeoPharm
- AstraZeneca
- GC Biopharma
- HANK Bioengineering
- Alkermes
- J&J
- Sanofi
- Lokon
- Endpoint Health